Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MONT-SAINT-GUIBERT, Belgium, April 22, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
-
First patient successfully dosed in expansion cohort of autologous CYAD-01 THINK trial for patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes...
-
MONT-SAINT-GUIBERT, Belgium, March 12, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
-
MONT-SAINT-GUIBERT, Belgium, March 02, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
-
MONT-SAINT-GUIBERT, Belgium, Feb. 17, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
-
Preliminary data from the Phase 1 CYCLE-1 trial are expected during second half 2020 MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq:...
-
Future development of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) program to be underpinned by proprietary OptimAb manufacturing processEnrollment of...
-
MONT-SAINT-GUIBERT, Belgium, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
-
Dr. Christian Homsy steps down from the Celyad Board of Directors as current CEO Filippo Petti is nominated into the role MONT-SAINT-GUIBERT, Belgium, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Celyad...
-
Funding will support the advancement of the Company’s autologous and allogeneic CAR-T cell therapy programs MONT-SAINT-GUIBERT, Belgium, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels...